Introduction: Cardiovascular disease remains the leading cause of death. Arterial hypertension is the main avoidable risk factor. Scientific societies advise control methods such as Ambulatory Blood Pressure Monitoring (ABPM) but this technique is not usually available in rural settings.The aim of this study was to evaluate the effectiveness of pharmaceutical intervention using ABPM in community pharmacies.
Material And Method: Observational study conducted in a rural community pharmacy between July 2021 and December 2023. Patients over 18 years of age who were normotensive or had a previous diagnosis of hypertension were selected. They were fitted with a MicrolifeWatch BP03 device for 29 hours. Patients with results compatible with HT were referred to their primary care physician.
Results: Twenty-one patients were included, of whom 20 were referred to the physician and treatment adjustments were made. Patient satisfaction was high, highlighting the accessibility of the service in the community pharmacy.
Conclusion: The accessibility and proximity of community pharmacies, especially in rural areas, facilitates the application of MAPA, improving the control of HTN.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11740889 | PMC |
| http://dx.doi.org/10.33620/FC.2173-9218.(2025).07 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effect of a calcium-channel blocker and β-blocker combination on reading-to-reading blood pressure variability: a randomized crossover trial.
Blood Press Monit
November 2024
Department of Cardiovascular Medicine, Centre for Epidemiological Studies and Clinical Trials, State Key Laboratory of Medical Genomics, Shanghai Key Laboratory of Hypertension, Shanghai Institute of Hypertension, National Research Centre for Translational Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Objective: The objective of this study was to investigate the efficacy of the nitrendipine/atenolol combination in comparison with standard-dose nitrendipine or atenolol monotherapy in reducing blood pressure (BP) and blood pressure variability (BPV) as assessed by ambulatory BP monitoring.
Methods: In a randomized, crossover trial, 32 patients (30-65 years) with grade 1 hypertension and elevated daytime reading-to-reading BPV were randomly assigned to receive either the nitrendipine/atenolol combination (10/20 mg) or standard-dose nitrendipine (10 mg) or atenolol (25 mg) monotherapy for 6 weeks, followed by a crossover to another treatment for 6 weeks.
Results: The final analysis included 31 patients (mean [±SD] age, 49.
[Impact of Ambulatory Blood Pressure Monitoring on patient health in remote areas: the role of Community Pharmacy].
Farm Comunitarios
January 2025
Farmacéutica Comunitaria en Grañón (La Rioja) España.
Introduction: Cardiovascular disease remains the leading cause of death. Arterial hypertension is the main avoidable risk factor. Scientific societies advise control methods such as Ambulatory Blood Pressure Monitoring (ABPM) but this technique is not usually available in rural settings.
View Article and Find Full Text PDFDoes Respiratory Sinus Arrhythmia Increase Nocturnal Blood Pressure?
Int Heart J
January 2025
Department of Research and Development, Tachikawa Medical Center.
By ambulatory blood pressure monitoring (ABPM), nocturnal blood pressure (BP) may increase before heart rate (HR), but the details are unknown.Among 102 participants who underwent ABPM, > 90% on hypertension treatment, the averaged BP (HR) data were examined for the time at which the BP (HR) increased significantly above the mean midnight BP (HR) between 3:00 AM - 9:00 AM in all patients and in subgroups divided by clinical variables. Participants were also divided according to the respiratory sinus arrhythmia (RSA) index, which is the ratio of the longest and shortest RR intervals obtained under normal breathing, and the effects of RSA on the nocturnal hemodynamics were examined.
View Article and Find Full Text PDFInvestigation of Factors for a Poor Prognosis in Rutherford 4 Patients Who Undergo Endovascular Treatment.
Int Heart J
January 2025
Department of Cardiology, Kameda Medical Center.
Current classifications of chronic limb-threatening ischemia (CLTI) are insufficient to identify Rutherford (R) 4 patients with a poor prognosis. This study aimed to investigate the prognostic factors for patients with R4 CLTI who undergo endovascular treatment (EVT) using data from the Tokyo-taMA peripheral vascular intervention research COmraDE (TOMA-CODE) registry and to propose a risk-scoring system. We analyzed the data of 2,248 prospectively enrolled patients from the registry, divided into 3 groups: intermittent claudication (IC), n = 1,185; R4, n = 401; and R5-6, n = 662.
View Article and Find Full Text PDFBackground: Contemporary methods of cardiovascular risk stratification are frequently inaccurate. Biomarkers such as high-sensitivity troponin I (hsTnI) have the potential to improve risk stratification. However, uncertainties exist regarding factors that determine hsTnI concentration.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!